نتایج جستجو برای: nras

تعداد نتایج: 2055  

Journal: :Cancer discovery 2013
Malin Pedersen Heidi V N Küsters-Vandevelde Amaya Viros Patricia J T A Groenen Berta Sanchez-Laorden Jacobus H Gilhuis Ilse A van Engen-van Grunsven Willy Renier Jolanda Schieving Ion Niculescu-Duvaz Caroline J Springer Benno Küsters Pieter Wesseling Willeke A M Blokx Richard Marais

UNLABELLED NRAS mutations are common in human melanoma. To produce a mouse model of NRAS-driven melanoma, we expressed oncogenic NRAS (NRAS(G12D)) in mouse melanocytes. When NRAS(G12D) was expressed in the melanocytes of developing embryos, it induced melanocyte proliferation and congenital melanocytic lesions reminiscent of human blue nevi but did not induce cutaneous melanoma. Unexpectedly, h...

2014
Christin E. Burd Wenjin Liu Minh V. Huynh Meriam A. Waqas James E. Gillahan Kelly S. Clark Brit L. Martin William R. Jeck George P. Souroullas David B. Darr Daniel C. Zedek Michael J. Miley Bruce C. Baguley Sharon L. Campbell Norman E. Sharpless

showed enhanced nucleotide binding, decreased intrinsic GTPase activity, and increased stability when compared with Nras G12D . This work identifi es a faithful model of human NRAS -mutant melanoma, and suggests that the increased melanomagenecity of Nras Q61R over Nras G12D is due to heightened abundance of the active, GTP-bound form rather than differences in the engagement of downstream effe...

2017
Andrea Cercek Maria Ignez Braghiroli Joanne F. Chou Jaclyn F. Hechtman Nancy Kemeny Leonard Saltz Marinela Capanu Rona Yaeger

Purpose: NRAS mutations are now routinely included in RAS testing prior to EGFR inhibitor therapy for metastatic colorectal cancer (mCRC). The clinical implications of NRAS mutation beyond lack of response to anti-EGFR therapy, however, are not known.We undertook this study to determine the clinical features and treatment outcomes of patients with NRAS-mutant mCRC. Experimental Design: We revie...

Journal: :Indian journal of biochemistry & biophysics 2014
Nageswara Rao Dunna Sugunakar Vuree Cingeetham Anuradha Kagita Sailaja Damineni Surekha Raghunadha Rao Digumarti V R Rao Satish Kumar Yadav Rajasekhar Reddy Satti Vishnupriya

The activating mutations of the Ras gene or other abnormalities in Ras signaling pathway lead to uncontrolled growth factor-independent proliferation of hematopoietic progenitors. Oncogenic mutations in NRAS gene have been observed with variable prevalence in hematopoietic malignancies. In the present study, NRAS mutations were detected using bidirectional sequencing in 264 acute leukemia cases...

2014
Zheng Xie Xiangxuan Liu Weipeng Wang Can Liu Zhengcao Li Zhengjun Zhang

TiO2 nanorod arrays (TiO2 NRAs) sensitized with CdS nanoparticles were fabricated via successive ion layer adsorption and reaction (SILAR), and TiO2 NRAs were obtained by oxidizing Ti NRAs obtained through oblique angle deposition. The TiO2 NRAs decorated with CdS nanoparticles exhibited excellent photoelectrochemical and photocatalytic properties under visible light, and the one decorated with...

2015
Arnaud Uguen Matthieu Talagas Sebastian Costa Laura Samaison Laure Paule Zarrin Alavi Marc De Braekeleer Cédric Le Marechal Pascale Marcorelles

BACKGROUND The determination of NRAS and BRAF mutation status is a major requirement in the treatment of patients with metastatic melanoma. Mutation specific antibodies against NRAS(Q61R) and BRAF(V600E) proteins could offer additional data on tumor heterogeneity. The specificity and sensitivity of NRAS(Q61R) immunohistochemistry have recently been reported excellent. We aimed to determine the ...

2017
Anastasios D Giannou Antonia Marazioti Nikolaos I Kanellakis Ioanna Giopanou Ioannis Lilis Dimitra E Zazara Giannoula Ntaliarda Danai Kati Vasileios Armenis Georgia A Giotopoulou Anthi C Krontira Marina Lianou Theodora Agalioti Malamati Vreka Maria Papageorgopoulou Sotirios Fouzas Dimitrios Kardamakis Ioannis Psallidas Magda Spella Georgios T Stathopoulos

The lungs are frequently affected by cancer metastasis. Although NRAS mutations have been associated with metastatic potential, their exact role in lung homing is incompletely understood. We cross-examined the genotype of various tumor cells with their ability for automatic pulmonary dissemination, modulated NRAS expression using RNA interference and NRAS overexpression, identified NRAS signali...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2017
Andrea Cercek Maria Ignez Braghiroli Joanne F Chou Jaclyn F Hechtman Nancy Kemeny Leonard Saltz Marinela Capanu Rona Yaeger

Purpose:NRAS mutations are now routinely included in RAS testing prior to EGFR inhibitor therapy for metastatic colorectal cancer (mCRC). The clinical implications of NRAS mutation beyond lack of response to anti-EGFR therapy, however, are not known. We undertook this study to determine the clinical features and treatment outcomes of patients with NRAS-mutant mCRC.Experimental Design: We review...

Journal: :Blood 2010
Benjamin Cuiffo Ruibao Ren

Activating mutations of NRAS are common in acute myeloid leukemia, chronic myelomonocytic leukemia, and myelodysplastic syndrome. Like all RAS proteins, NRAS must undergo a series of post-translational modifications for differential targeting to distinct membrane subdomains. Although farnesylation is the obligatory first step in post-translational modifications of RAS, to date, successes of the...

2016
Michael K. Kiessling Alessandra Curioni-Fontecedro Panagiotis Samaras Silvia Lang Michael Scharl Adriano Aguzzi Derek A. Oldridge John M. Maris Gerhard Rogler

High-risk neuroblastoma remains lethal in about 50% of patients despite multimodal treatment. Recent attempts to identify molecular targets for specific therapies have shown that Neuroblastoma RAS (NRAS) is significantly mutated in a small number of patients. However, few inhibitors for the potential treatment for NRAS mutant neuroblastoma have been investigated so far. In this in-vitro study, ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید